Tài liệu Báo cáo khoa học: An immunomodulator used to protect young in the pouch of the Tammar wallaby, Macropus eugenii pptx

Eugenin
An immunomodulator used to protect young in the pouch of the
Tammar wallaby, Macropus eugenii
Russell V. Baudinette
1,
*, Pinmanee Boontheung
2
, Ian F. Musgrave
3
, Paul A. Wabnitz
2
,
Vita M. Maselli
2
, Jayne Skinner
1
, Paul F. Alewood
4
, Craig S. Brinkworth
2
and John H. Bowie
2
1 Department of Environmental Biology, The University of Adelaide, South Australia
2 Department of Chemistry, The University of Adelaide, South Australia
3 Department of Clinical and Experimental Pharmacology, The University of Adelaide, South Australia
4 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
Marsupials are born in an immature state and many
of the developmental processes that occur in these
mammals take place during pouch life [1]. After a
short period of intrauterine development, the young
marsupial crawls unaided to the mother’s pouch, atta-

ches to a teat, and undergoes further development in
an aerial environment [2] (Fig. 1). The pouch microcli-
mate is characterized by high humidity, and a constant
temperature close to maternal body temperatures [3].
The pouch, with its warm, moist environment, is a
favourable environment for microorganisms. It has
been shown that a variety of Gram-positive bacilli are
present in marsupial pouches, together with lesser
amounts of Gram-negative bacilli [4,5]. The bacterial
content of the pouch diminishes significantly upon
arrival and occupancy of the young marsupial [6].
When the young first crawls into the pouch, it has
essentially no immune system of its own and must
rely on that provided by the mother [1,7], even
though it has been reported that an immunoglobulin
is present in fetal and newborn sera of the Tammar
wallaby (Macropus eugenii) [7]. With increasing devel-
opment, the young produces its own immune system.
For example, T and B cells are first detected 50 days
into the development of the young wallaby in the
pouch [7], and it has been shown that cholecystokinin
8 (CCK8) (a neuropeptide which engenders T and B
cell proliferation) is present in the brains of mature
Keywords
eugenin; immunomodulator; lactating
female; Tammar wallaby (Macropus eugenii)
Correspondence
J. H. Bowie, Department of Chemistry, The
University of Adelaide, South Australia, 5005
Fax: +61 08 83034358

Tel: +61 08 83035767
E-mail:
*Author deceased
(Received 30 August 2004, revised 18
October 2004, accepted 16 November
2004)
doi:10.1111/j.1742-4658.2004.04483.x
Eugenin [pGluGlnAspTyr(SO
3
)ValPheMetHisProPhe-NH
2
] has been
isolated from the pouches of female Tammar wallabies (Macropus eugenii)
carrying young in the early lactation period. The sequence of eugenin
has been determined using a combination of positive and negative ion
electrospray mass spectrometry. This compound bears some structural
resemblance to the mammalian neuropeptide cholecystokinin 8
[AspTyr(SO
3
)MetGlyTrpMetAspPhe-NH
2
] and to the amphibian caerulein
peptides [caerulein: pGluGlnAspTyr(SO
3
)ThrGlyTrpMetAspPhe-N H
2
].
Eugenin has been synthesized by a route which causes only minor hydrolysis
of the sulfate group when the peptide is removed from the resin support. Bio-
logical activity tests with eugenin indicate that it contracts smooth muscle at a

concentration of 10
)9
m, and enhances the proliferation of splenocytes at
10
)7
m, probably via activation of CCK
2
receptors. The activity of eugenin
on splenocytes suggests that it is an immunomodulator peptide which plays a
role in the protection of pouch young.
Abbreviations
CCK-8, cholecystokinin 8; CCK-8-NS, cholecystokinin 8 nonsulfated; QTOF, quadrupole-time-of-flight; splenocyte, spleen derived lymphocyte;
TFA, trifluoroacetic acid.
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 433
marsupials (including the Tammar wallaby) [8]. There
is thus an apparent conflict due to the seemingly
unprotected young crawling into, and subsequently
developing in, a pouch abundant with harmful micro-
organisms.
There are three possible scenarios which may explain
how the female wallaby protects the young during the
early period of occupancy in the pouch. She may have
antimicrobial and other biologically active agents in
her milk, there may be host defence compounds in the
secretion contained in the pouch, or there may be host
defence compounds in the saliva, which she deposits
when licking the pouch. It is known that (a) there are
antimicrobial peptides in the pouch of the koala
(Phascolarctos cinereus) [9], and (b) there are anti-
microbially active proteins and peptides, including

immunoglobulins, lysozyme and other antibacterial
enzymes, in the milk of higher animals [7,10–18]. In
this context, marsupial whey proteins have been exam-
ined as a function of the time when they are present
during the lactation period [19–25]; generally the pro-
tein content varies significantly from the early to the
late lactation period.
Female wallabies produce a waxy secretion in the
pouch, and the constituency of this secretion appears
to depend upon the oestrus cycle and the time the
young has spent in the pouch [6]. There is also evi-
dence that polyprotodont opossums produce immuno-
globulins in the pouch [26]. Whether immunoglobulins
are secreted into the pouch of diprotodonts such as
the Tammar wallaby is yet to be established.
In this paper we report a study of the low molecular
mass (< 2000 Da) water-soluble components of swabs
taken from the pouch of the Tammar wallaby [27],
with a view to identifying any maternal defence com-
pounds (e.g. antimicrobial agents and ⁄ or neuropep-
tides) in the pouch. We describe a unique mammalian
cholecystokinin (CCK)-like peptide, eugenin, which
may act as an immunomodulator.
Results
The pouch swabs of female wallabies with or without
young in the pouch, contain low molecular mass
(< 2000 Da) water-soluble compounds. Figure 2 shows
a typical HPLC separation. MS and MS ⁄ MS data on
the components of all HPLC fractions indicate the
presence of a variety of lipid, sugar and phosphate

Fig. 1. The young of Macropus eugenii (A)
climbing into the pouch and (B) attached to
a teat.
Fig. 2. HPLC of aqueous extract of pouch secretion from female
Macropus eugenii carrying young during the early lactation period.
Peak marked with an asterisk contains eugenin.
Protection by eugenin of Macropus eugenii young R. V. Baudinette et al.
434 FEBS Journal 272 (2005) 433–443 ª 2005 FEBS
containing systems which have not been fully character-
ized. None of these fractions show antimicrobial activity
at MIC values below 100 lgÆmL
)1
, and with the excep-
tion of one component, they have not been studied fur-
ther. The exception is the only peptide identified (by
MS ⁄ MS data) from the pouch swabs. This peptide was
isolated in lg amounts from pouch swabs taken from
early lactating females in the first two weeks of the occu-
pancy of young in the pouch. We have called this peptide
eugenin. Eugenin was not detected, following exhaustive
monitoring, in pouch swabs from female Tammar
wallabies that were either (a) not carrying young, or (b)
were bearing young, but after the early lactation period
(i.e. after the young had been resident in the pouch for
more than two weeks). Monitored HPLC profiles of
pouch swabs not containing eugenin were almost identi-
cal with that shown in Fig. 2, except that the fraction
corresponding to that designated with an asterisk
(Fig. 2), is reduced in abundance to the baseline.
Structure determination of eugenin

Because eugenin has an N-terminal pGlu residue,
automated Edman sequencing [28] cannot be used to
determine the amino acid sequence of this peptide.
Sequence analysis was effected using positive and neg-
ative ion electrospray mass spectrometry.
The negative ion mass spectrum of eugenin gives
peaks corresponding to (M-H)
–
and [(M-H)
–
-SO
3
]
–
at
m ⁄ z 1371 and 1291, respectively, indicating that euge-
nin has a molecular mass of 1372 Da, and that it con-
tains a sulfate group. The positive ion mass spectrum
shows a small MH
+
ion at m ⁄ z 1373, and a pro-
nounced peak corresponding to an [MH
+
-SO
3
]
+
spe-
cies at m ⁄ z 1293. The collision induced mass spectrum
(MS ⁄ MS) of the [MH

+
-SO
3
]
+
ion is recorded in
Fig. 3. A partial amino acid sequence for eugenin was
determined using B and Y+2 fragmentations (positive
ion fragmentations of peptides reviewed in [29]). The B
fragmentations are indicated schematically above the
spectrum and provide information concerning the
sequence from the C-terminal end of the peptide, while
the Y+2 fragmentations (shown schematically under-
neath the spectrum) provide sequencing data from the
N-terminal end of the peptide. The positive ion mass
spectrum (Fig. 3) provides the majority of the sequence
except that it does not identify the first two residues at
the N-terminal end of the peptide.
Fig. 3. Positive ion mass spectrum (MS ⁄ MS) of the [MH
+
–SO
3
]
+
ion of eugenin. B and Y+2 fragmentation sequences are indicated schema-
tically above and below the spectrum, respectively. (Positive ion cleavages of peptides discussed in [29]). Figure scaled as follows: m ⁄ z
1286–1042 (·15), 1042–994 (·5), 994–772 (·15), 759–624 (·10), 317–175 (·5). Micromass QTOF2 instrument.
R. V. Baudinette et al. Protection by eugenin of Macropus eugenii young
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 435
The collision induced negative ion mass spectrum

(MS ⁄ MS) of the [(M-H)
–
-SO
3
]
–
ion of eugenin is
shown in Fig. 4. There are a number of backbone
cleavages in negative ion spectra which provide
sequencing information. These have been described
previously [30]. Two of these (a and b cleavages) are
fragmentations of amide moieties, and give infor-
mation analogous to that provided by B and Y+2
cleavages in the corresponding positive ion spectra.
The other backbone cleavages (d and c processes) ori-
ginate from Asp, Asn, Glu or Gln side chains and
provide specific information concerning the positions
of these four residues. The d and c fragmentations
are particularly important in identifying Gln residues,
because isobaric Gln and Lys cannot be differentiated
by low resolution positive ion mass spectrometry. The
a and b derived sequences are indicated schematically
above and below the negative ion spectrum shown in
Fig. 4, while d and c cleavages are indicated on the
spectrum. The data shown in Fig. 4 gives the
sequence of eugenin except that it does not indicate
the relative orientation of residues 6 and 7. The spec-
trum identifies pGlu as residue 1 and shows that resi-
due 2 is Gln rather than Lys. A combination of the
fragmentation data from the negative and positive ion

spectra give the full sequence of eugenin (for
sequence, see Table 1).
Synthesis of eugenin
Eugenin was synthesized to confirm the structure of
the compound, and to provide sufficient material to
allow biological testing to be performed.
The synthesis of tyrosine sulfate containing peptides
can be challenging because of possible hydrolysis of
the sulfate residue occurring during synthesis, in
Table 1. Eugenin, and mammalian and amphibian analogues.
Sequence Name
pGluGlnAspTyr(SO
3
)ValPheMetHis-
ProPhe-NH
2
Eugenin
AspTyr(SO
3
)MetGlyTrpMetAspPhe-NH
2
Cholecystokinin-8 [37]
Tyr(SO
3
)GlyTrpMetAspPhe-NH
2
Hexagastrin [38]
pGluGlnAspTyr(SO
3
)ThrGlyTrpMetAsp-

Phe-NH
2
Caerulein [39,40]
pGluGlnAspTyr(SO
3
)ThrGlyTrpPheAsp-
Phe-NH
2
Caerulein 1.2 [41]
pGluAsnAspTyr(SO
3
)LeuGlyTrpMetAsp-
Phe-NH
2
D
2
L
5
-Caerulein [58]
pGluGluTyr(SO
3
)ThrGlyTrpMetAspPhe-NH
2
Phyllocaerulein [59]
Fig. 4. Negative ion mass spectrum of the [(M-H)
–
-SO
3
]
–

ion of eugenin. a and b fragmentation sequences are drawn schematically above
and below the spectrum, respectively. d and c cleavages are shown on the spectrum. (Backbone cleavage ions in negative ion spectra
discussed in [30]). Figure scaled as follows: m ⁄ z 1284–1044 (·80), 1012–561 (·10), 560–248 (·5), 247–52 (·50). Micromass QTOF2
instrument.
Protection by eugenin of Macropus eugenii young R. V. Baudinette et al.
436 FEBS Journal 272 (2005) 433–443 ª 2005 FEBS
particular when the synthesized peptide is removed
from the resin support. It has been reported that the
peptide-resin cleavage and the removal of protecting
groups can be effected using trifluoroacetic acid (TFA)
at low temperature with only minimal damage to the
Tyr(SO
3
) residue [31,32]. The procedure used for the
synthesis of eugenin is a modification of the reported
methods, and is outlined in detail in Experimental pro-
cedures. The key step involves treating the peptide-
resin with TFA ⁄ tri-isopropyl silane (9 : 1) at 4 °C for
2.5 h under nitrogen, a method which releases the
deprotected peptide from the resin with only minor
hydrolysis of the Tyr(SO
3
) residue. Preparative HPLC
of the reaction product gives analytically pure eugenin,
MH
+
¼ 1373 Da. Synthetic and natural eugenin were
shown to be identical by negative and positive ion
mass spectrometry (MS and MS ⁄ MS) and HPLC.
Biological testing

As eugenin had similar structural elements to both
CCK and caerulein, known CCK receptor agonists, we
performed biological activity screening in tissues with
well-characterized CCK responses.
Contraction studies
Acetylcholine contracted guinea pig ileal segments in
a concentration-dependent fashion (data not shown).
The mixed CCK
1
CCK
2
receptor agonist and standard
CCK-8 produced potent increases in contraction, was
maximally effective at 10
)9
m, but produced only
about 60% of the contraction produced by the
maximally effective concentration of acetylcholine
(Fig. 5A). The CCK
2
agonist and standard cholecy-
stokinin 8 nonsulfated (CCK-8-NS) also produced
increases in contraction, but was less potent and less
effective than CCK-8 (Fig. 5A). These results are con-
sistent with previous studies [33]. Eugenin also pro-
duced an increase in contraction, and was equieffective
and equipotent with CCK-8-NS (Fig. 5A). This sug-
gested that eugenin might be acting as a CCK
2
agon-

ist. As the contraction produced by CCK
2
agonists is
due to the release of acetylcholine from cholinergic
nerve terminals, the effects of eugenin and CCK-8
were determined in the presence of atropine (10
)6
m).
This concentration of atropine was sufficient to com-
pletely block the effects of the maximally effective con-
centration of acetylcholine (data not shown). Atropine
had no effect on the contraction produced by CCK-8.
However atropine completely stopped the contraction
produced by 10
)8
m eugenin and substantially reduced
the contraction produced by 10
)7
m eugenin (Fig. 5B).
Spleen derived lymphocyte proliferation studies
The result that eugenin is a CCK
2
agonist has import-
ant implications for maternal defense of the pouch
young. Lymphocytes have CCK
2
receptors, which
when stimulated, result in proliferation. Spleen derived
lymphocyte (splenocyte) proliferation was assessed
using the Alamar Blue fluorescence dye method [34].

CCK-8 produced a concentration dependent increase
in lymphocyte proliferation in both the presence
(Fig. 6A) and absence (data not shown) of the mito-
gen concanavalin A. CCK-8-NS was less effective
(Fig. 6A). This is consistent with previous studies
[35,36]. Eugenin (and to a lesser extent, desulfated
eugenin) also produced a concentration dependent
increase in lymphocyte proliferation in both the pres-
Fig. 5. (A) CCK-8 (d), CCK-8-NS (h) and eugenin ( ) concentration–
response curves in guinea pig ileum. Ileal segments were exposed
to increasing concentrations of CCK-8, CCK-8-NS and eugenin. Con-
tractions were measured on a Maclab data recorder (Maclab, Castle
Hill, New South Wales, Australia) and expressed as a percentage
of the maximal acetylcholine response (10
)6
M; 56 ± 15 mm). Data
are expressed as mean ± SD of three independent experiments.
(B) The effect of atropine on contractions produced by CCK-8 and
eugenin in guinea pig ileum. Ileal segments were exposed to either
vehicle or atropine (10
)6
M) for 15 min then CCK-8 or eugenin
applied. Contractions were measured on a Maclab data recorder
and expressed as a percentage of the maximal acetylcholine
response (10
)6
M; 86 ± 15 mm). Data are expressed as mean ± SD
of two experiments, except for eugenin vehicle, where n ¼ 1.
R. V. Baudinette et al. Protection by eugenin of Macropus eugenii young
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 437

ence (Fig. 6B) and absence (data not shown) of conca-
navalin A.
Discussion
Eugenin is the only peptide detected in aqueous
extracts of pouch swabs of the Tammar wallaby. Euge-
nin has a sequence related to those of the mammalian
gastrin-like neuropeptides CCK-8 [37] and hexagastrin
[38] (Table 1). Eugenin also shows significant similarity
to the amphibian caerulein neuropeptides [39–41].
CCK-8 and caerulein have similar physiological activ-
ity; they both show potent smooth muscle contraction,
gastrin-like activity and they reduce blood pressure at
concentrations as low as ngÆkg
)1
of body weight.
Caerulein is an analgesic several thousand times more
potent than morphine [40]. CCK-8 and caerulein both
contain a tyrosine sulfate residue; the bioactivity is
diminished if the tyrosine sulfate group is hydrolysed
[40]. Eugenin corresponds to the caeruleins in having
the same first four residues, but the sequence after the
Tyr(SO
3
) residue of eugenin is different from those of
the other mammalian and amphibian analogues shown
in Table 1.
CCK-8 and caerulein bind to CCK receptors [42].
There are two types of CCK receptor, CCK
1
and

CCK
2
, differing in anatomical locations and actions
[43]. The sequences of the CCK receptors are known
[44] and representations of their 3D structures have
been reported [44,45]. Both NMR and other experi-
mental data have been used to determine where CCK-
8 binds on the receptors [44–47]. In the present study
we use CCK-8 and its desulfated analogue (CCK-8-
NS) as standards.
CCK-8 and caerulein activate both CCK receptors:
perhaps eugenin may act via one or both CCK receptor
subtypes. In the guinea pig ileum, CCK receptor agon-
ists act to cause contraction of smooth muscle [33].
CCK
1
receptors are present on the smooth muscle, and
contract the smooth muscle directly. In contrast, CCK
2
receptors act indirectly, by causing the release of acetyl-
choline from cholinergic nerves in the myenteric plexus,
which activates muscarinic receptors on smooth muscle
[33]. In the present study, the standard neuropeptide
CCK-8, which activates CCK
1
and CCK
2
receptors,
produced a concentration dependent increase in
contraction of guinea pig isolated ileal segments. CCK-

8-NS, which is selective for CCK
2
receptors, also pro-
duced concentration dependent contraction of ileal
segments but was less potent and effective than CCK-8.
These results are consistent with the results of Patel
et al. [33]. Eugenin produced a concentration depend-
ent contraction of ileal smooth muscle segments, with a
similar potency to that of CCK-8-NS.
To determine if eugenin acts through CCK
2
recep-
tors, the effect of the muscarinic blocker atropine was
investigated. Atropine had no effect on the response of
CCK-8, but substantially reduced the response to euge-
nin, indicating that eugenin is indeed acting through
CCK
2
receptors.
To further investigate the interaction of eugenin with
CCK
2
receptors, we investigated the effect of eugenin
on lymphocyte proliferation. Lymphoid cells have
CCK
2
receptors exclusively [43,48], and exposure of
lymphoid tumour cell lines [35] or mouse lymphocytes
[36] to CCK agonists results in lymphocyte prolifer-
Fig. 6. (A) CCK-8 (d) and CCK-8-NS (s) concentration–response

curves in mouse splenocytes. Splenocytes were exposed to
increasing concentrations of CCK-8, or a single concentration of
CCK-8-NS in the presence of the mitogen concanavalin A. Lympho-
cyte proliferation was measured by the increase in fluorescence
due to conversion of Alamar Blue [37]. Data shown are from a sin-
gle experiment performed in quadruplicate, representative of two
experiments carried out in quadruplicate. (B) Eugenin (
) and euge-
nin-NS (h) concentration-response curves in mouse lymphocytes.
Lymphocytes were exposed to increasing concentrations of euge-
nin in the presence of the mitogen concanavalin A. Lymphocyte
proliferation was measured by the increase in fluorescence due to
conversion of Alamar Blue. Data were expressed as a percentage
of the CCK maximum response (10
)5
M, performed in the same
time period with each run). Values are the mean ± SD of four
experiments for eugenin.
Protection by eugenin of Macropus eugenii young R. V. Baudinette et al.
438 FEBS Journal 272 (2005) 433–443 ª 2005 FEBS
ation. In these experiments, exposure of mouse spleno-
cytes to the standard neuropeptide CCK-8 resulted in
a concentration dependent increase in proliferation, as
measured by the Alamar Blue assay [34]. These results
are consistent with previous studies [35,36] (although
Medina et al. [36] found CCK-8 to be more potent
than in the current study, the cells were exposed to
CCK agonists for 72 h compared to 24 h in this
study). CCK-8-NS produced proliferation, but was less
potent than CCK-8. Eugenin also produced an

increase in proliferation, equieffective with CCK-8,
while desulfated eugenin shows a much reduced
response (Fig. 6B). These results are consistent with
eugenin being a CCK
2
agonist.
These results provide insight concerning the possible
role of eugenin in the wallaby pouch. Eugenin is only
observed during the early lactation period (i.e. when
the young has no immune system of its own), when
there is a profound fall in the microbial flora of the
pouch [6]. Neither eugenin nor other low molecular
mass components of the pouch have antibacterial
properties per se. However the skin is also an active
immune tissue, and as CCK
2
receptors have a role in
stimulating immune cells [35,36,49], eugenin may act
to stimulate the immune cells in the skin. As well as
stimulation of the proliferation of lymphocytes, activa-
tion of CCK receptors stimulate production of inter-
leukins and secretion of immunoglobulins on the
mucosal surface of the intestine [49,50]. The antibacte-
rial defence of the intestinal mucosa depends in part
on stimulation of CCK receptors [49].
From a consideration of the experimental data, we
suggest that eugenin stimulates immune cells in the
pouch of the Tammar wallaby in the early lactation per-
iod, thus reducing bacterial flora numbers in the pouch.
Experimental procedures

Pouch swabs
Cotton wool swabs of the pouches of three female M. euge-
nii were taken at two day intervals, from two days before
the young occupies the pouch until the pouch had been
occupied for two weeks, and then weekly for the next four
weeks. Each swab was shaken with deionized water
(50 mL), the mixture diluted with an equal volume of meth-
anol, centrifuged, filtered through a Millex HV filter unit
(0.45 lm), and lyophilized (the methanol was added to
denature and precipitate any enzymes which may effect
degradation of active pouch components). This procedure
provided, on average, 1–2 mg of solid material from each
swab. Swabs were also taken, for comparison, from
pouches of female M. eugenii that were not bearing young.
HPLC separation of pouch material
HPLC separation of pouch material was achieved using a
VYDAC C18 HPLC column (5l, 300A, 4.6 · 250 mm)
(Separations Group, Hesperia, CA, USA) equilibrated with
10% acetonitrile ⁄ aqueous 0.1% TFA. The lyophilized mix-
ture (generally  1 mg) was dissolved in deionized water
(50 lL), of which a 10 lL fraction was injected into the
column. The elution profile was generated using a linear
gradient produced by an ICI DP 800 Data Station control-
ling two LC1100 HPLC pumps, increasing from 10 to 75%
(v ⁄ v) acetonitrile over a period of 60 min at a flow rate of
1mLÆmin
)1
. The eluant was monitored by ultraviolet
absorbance at 214 nm using an ICI LC-1200 variable wave-
length detector (ICI Australia, Melbourne, Australia). An

HPLC trace is shown in Fig. 2. All fractions of all HPLC
traces were monitored using positive ion electrospray mass
spectrometry. MS and MS ⁄ MS data were obtained for all
components of all HPLC fractions (see below for details of
MS procedures). Eugenin was isolated from HPLC traces
of animals in the first two weeks of lactation. The fraction
containing eugenin is indicated by an asterisk in Fig. 2.
Two further HPLC separations of the initial eugenin frac-
tion (10–75% acetonitrile over a period of 60 min at a flow
rate of 1 mLÆmin
)1
.) were required in order to obtain a
pure eugenin. The eugenin fraction was collected, concen-
trated and dried in vacuo providing 15 lg of pure eugenin.
Electrospray mass spectrometry
Positive and negative electrospray mass spectra were meas-
ured with a Micromass QTOF2 orthogonal acceleration
quadrupole-time-of-flight mass spectrometer (Micromass,
Manchester, UK) with a mass range to 10 000 Da. The
QTOF2 is fitted with an electrospray source in an ortho-
gonal configuration with the ZSPRAY interface. Samples
were dissolved in acetonitrile ⁄ water (1 : 1, v ⁄ v) and infused
into the electrospray source with a flow rate of 5 lLÆmin
)1
.
Conditions were as follows: capillary voltage 2.43 kV,
source temperature 80 °C, desolvation temperature 150 °C
and cone voltage 50–100 V. MS ⁄ MS data were acquired
with the argon collision gas energy set to 50eV to give opti-
mal fragmentation.

Preparation of synthetic eugenin [pGluGlnAsp-
Tyr(SO
3
)ValPheMetHisProPhe-NH
2
]
Materials
Manual syntheses were performed with Fmoc-amino acids
purchased from Bachem, Novabiochem and Aspen (Aspen,
CO, USA). The Ramage Amide tricyclic linker was pur-
chased from Bachem. Diisopropylcarbodiimide was from
Aldrich (Castle Hill, New South Wales, Australia) and
2-(1H-benzotriazol-1-yl)-1 ,1,3,3-tetramethyl-uroniumhexafluoro-
R. V. Baudinette et al. Protection by eugenin of Macropus eugenii young
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 439
phosphate was obtained from Richelieu Biotechno-
logies (Quebec City, Quebec, Canada). N,N-diisopropyl-
ethylamine, N,N-dimethylformamide, dichloromethane,
piperidine, TFA and Fmoc-sulfotyrosine (all peptide syn-
thesis grade) were purchased from Auspep (Melbourne,
Australia). Acetone (HPLC grade) was obtained from
Water Millipore (Milford, MA, USA). High purity water
was generated by a Milli-Q
TM
purification system (Milli-
pore, Bedford, MA, USA). Screw-cap glass peptide synthe-
sis reaction vessels (20 mL) with a #2 sintered glass filter
frit and a shaker for manual solid-phase synthesis were
obtained from Embel Scientific Glassware (Brisbane,
Queensland, Australia).

Protocol and chain assembly
The solid-phase peptide synthesis of eugenin was conducted
manually on a 0.25 mmol scale by a standard method
which has been reported earlier [51,52]. The determination
of residual free a-amino groups following each cycle was
monitored by the quantitative Ninhydrin test [53], except
for couplings to proline where a coupling efficiency of
> 99.5% was achieved as shown by Isatin tests [54,55].
Deprotection and removal from resin
The peptide-resin (337 mg) was treated with TFA
(61.2 mL) in triisopropylsilane (6.8 mL) (9 : 1, v ⁄ v) at 4 °C
for 2.5 h. The resin was removed and the TFA solution
was concentrated under nitrogen. The crude peptide was
washed with diethyl ether (10 mL), dissolved in aqueous
acetonitrile [50%, 20 mL, containing 0.1% (v ⁄ v) TFA] and
lyophilized to give a white powder (18 mg) [31,32].
HPLC analysis
The peptide mixture (9 mg) was purified by preparative
HPLC using a Vydac C18 column (10 lm, 2.2 · 25 cm).
Chromatographic separations were achieved using linear gra-
dients of solvent B in A at a flow of 8 mLÆmin
)1
with
25–45% B over 40 min: solvent A, 100% water, 0.05% (v ⁄ v)
TFA; solvent B, 90% (v ⁄ v) aqueous acetonitrile, 0.043%
(v ⁄ v) TFA. The eluant was monitored at 230 nm. Lyophiliza-
tion of the separated fractions gave eugenin (6 mg) [identical
in HPLC retention time and mass spectra (both negative and
positive ion) with natural eugenin] and desulfated eugenin
(2 mg) (pGluGlnAspTyrValPheMetHisProPhe-NH

2
).
Bioactivity assays
Antimicrobial testing on HPLC fractions and synthetic euge-
nin was carried out by the Microbiology Department of the
Institute of Medical and Veterinary Science (Adelaide,
Australia) using a standard procedure [56]. The microorgan-
isms used were: Bacillus cereus, Escherichia coli, Leuconostoc
lactis, Listeria innocua, Micrococcus luteus, Pasteurella multo-
cida, Staphylococcus aureus, Staphylococcus epidermidis and
Streptococcus uberis. Neither the HPLC fractions nor euge-
nin showed activity at an MIC value of 100 lg Æ mL
)1
against
any of these organisms, and is thus deemed inactive.
Contraction studies
Drugs and materials
This work was approved by The University of Adelaide
Animal Ethics Committee.
Acetylcholine, atropine, concanavalin A, CCK-8 and
CCK-8-NS were obtained from Sigma-Aldrich. Alamar blue
was obtained from Astral Scientific (Caringbar, New South
Wales, Australia).
Guinea pigs weighing approximately 300 g were used.
Immediately before the experiment, the guinea pigs were
killed by stunning and subsequent decapitation. The ileum
was dissected free and was cleansed by rinsing with physiolo-
gical salt solution (composition in mm): KCl 2.7, CaCl
2
1.0,

NaHCO
3
13.0, NaH
2
PO4 3.2, NaCl 137, glucose 5.5
(pH 7.4), and mesenteric tissue was removed. Segments of
about 3 cm were cut, which were suspended in 20 mL organ
baths containing the physiological salt solution and were
gassed with 95% O
2
and 5% CO
2
. Segments were connected
to a tissue holder and to an isometric force-displacement
transducer. Tension was recorded via maclab v 3.0. Seg-
ments were washed thoroughly by replacing the physiological
salt solution repeatedly, and were then allowed to equilibrate
for a period of 30 min under 2 g of resting tension. Supply
reservoirs and organ baths were maintained at 37 °C and
were gassed with O
2
⁄ CO
2
as outlined above.
Following the 30 min equilibration period, the tissue-
bathing solution was replaced repeatedly with fresh drug-
free physiological salt solution until a stable baseline
tension was achieved. The tension was then readjusted to
2 g. All segment preparations were then constricted with
acetylcholine (0.01–1 lm). After washout, acetylcholine

(1 lm) was used again to check that the response was sta-
ble. After 5 min washout and achievement of a stable base-
line, a cumulative response curve to CCK-8 (10
-10
)10
-8
m)
was performed. After another 5 min washout and achieve-
ment of a stable baseline, a cumulative concentration
response curve to either eugenin (10
-9
)10
-7
m) or CCK-8-
NS (10
-9
)10
-7
m) was performed. In some experiments, fol-
lowing washout, tissues were either pretreated with atropine
or vehicle and CCK-8 or eugenin reapplied.
Splenocyte proliferation studies
Male Balb ⁄ C mice aged 6–8 weeks were used. Lymphocytes
were prepared as described previously [57] with minor
modifications. Aseptic techniques were used during
Protection by eugenin of Macropus eugenii young R. V. Baudinette et al.
440 FEBS Journal 272 (2005) 433–443 ª 2005 FEBS
preparation of the lymphocytes. Mice were killed by cervi-
cal dislocation followed by prompt removal of the spleen.
The spleen was prepared as a single-cell suspension by mas-

saging and washing through a nylon mesh into a 15 mL
tube with up to 15 mL of RPMI 1640 (Hepes modification,
0.3 mgÆmL
)1
of l-glutamine and 5 mL of penicillin ⁄ strepto-
mycin solution per litre). The cells were centrifuged at 4 °C
for 5 min at 100 g, the supernatant material discarded and
the cells resuspended in 1 mL of media followed by the
addition of 10 mL of ice-cold lysis buffer (1 mL of
20.56 gÆL
)1
tris base (pH 7.65), 9 mL of 0.83% NH
4
Cl in
water, mixed just prior to addition to cells). The suspension
was placed on ice for 4 min, centrifuged (5 min at 100 g)
and the supernatant material discarded. The suspensions of
cells were pooled and were resuspended in 10 mL of media
followed by centrifugation (5 min at 100 g), removal of
supernatant material and resuspended in 5 mL of enriched
RPMI 1640 (RPMI 1640 enriched with 10% fetal bovine
serum). The number of viable lymphocytes in the suspen-
sion was counted using trypan blue and a haemocytometer.
Cells were then diluted in enriched media to 1 · 10
6
cellsÆ
mL
)1
and 100 lL of this suspension was added to each well
of the 96 multiwell plates (TTP, Zurich, Switzerland) to

give a final volume of 200 lL, and final cell count of
50 000 cells per well.
Either vehicle or the mitogen concanavalin 1 (2.5 lgÆmL
)1
final concentration) was added to the wells, and then 10 lL
of RPMI 1640 medium containing either CCK-8, CCK-8-NS
or eugenin (to produce final concentrations of 10
-7
)10
-5
m)
was added to the plate. Plates were incubated at 37 °C, using
5% CO
2
in a humidified incubator (Thermoline, Sydney,
New South Wales, Australia) for 24 h. Twenty-five microlit-
ers of the mitochondrial activity indicator dye Alamar Blue
[34] was then added to give a final concentration of
2.5 lgÆmL
)1
, and the plates incubated as above for a further
4 h. After this, 175 lL aliquots were pipetted from each well
into a white 96 well plate, and fluorescence measured in a
Polestar Galaxy (BMG Labtechnologies, Durham, NC,
USA) fluorescent plate reader (excitation 544 nm, emission
590 nm).
Acknowledgements
We thank the Australian Research Council for provi-
ding maintenance funding for this project. The ARC
also provided the following stipends: C.S.B. (research

associate), V.M.M. and P.A.W. (postgraduate scholar-
ships).
References
1 Deane EM & Cooper DW (1988) Immunological devel-
opment of pouch young marsupials. In The Developing
Marsupial – Models for Biomedical Research (Tyndale-
Briscoe CH & Janssens PA, eds) pp. 190–199. Springer
Verlag, Berlin, Germany.
2 Deane EM & Cooper DW (1984) Immunology of pouch
young marsupials. 1. Levels of immunoglobulins, trans-
ferrin and albumin in the blood and milk of euros and
wallaroos (Hill kangaroos: Macropus robustus; Marsu-
pialia). Dev Comp Immunol 8, 863–876.
3 Baudinette RV, Gannon BJ, Ryan RG & Frappell PB
(1988) Changes in metabolic rates and blood respiratory
characteristics during pouch development of a marsu-
pial, Macropus eugenii. Respir Physiol 72, 219–224.
4 Yadav M, Stanley NF & Waring H (1972) The micro-
bial flora of the gut of the pouch-young and pouch of a
marsupial, Setonix brachyurus. J General Microbiol 70,
437–442.
5 Charlick J, Manessis C, Stanley N, Waring H & Cock-
son A (1981) Quantitative alterations of the aerobic bac-
terial flora of the pouch of Setonix brachurus (quokka)
during oestrus, anoestrus, pregnancy and lactating
anoestrus (pouch young). Aust J Exp Biol Med Sci 51,
743–751.
6 Old JM & Deane EM (1998) The effect of oestrus and
the presence of pouch young on aerobic bacterial iso-
lated from the pouch of the tammar wallaby, Macropus

eugenii. Comp Immunol Microbiol Infect Dis 21, 237–
245.
7 Old JM & Deane EM (2000) Development of the
immune system and immunological protection in marsu-
pial pouch young. Dev Comp Immunol 24, 445–454.
8 Fan ZW, Eng J, Shaw G & Yalow RS (1988) Cholecys-
tokinin octapeptide purified from brains of Australian
marsupials. Peptides 9, 429–431.
9 Bobek G & Deane EM (2002) Possible antimicrobial
compounds from the pouch of the koala, Phascolartos
cinereus. Lett Peptide Sci 8, 133–137.
10 McKenzie HA & Shaw DC (1985) The amino acid
sequences of equine milk lysozyme. Biochem Int 10, 23–31.
11 Carlsson A, Bjorck L & Persson K (1989) Lactoferrin
and lysozyme in milk during acute mastitis and their inhi-
bitory effect in Delvotest P. J Dairy Sci 72, 3166–3175.
12 Koldovsky O (1989) Search for role of milk-borne bio-
logically active peptides for the suckling. J Nutr 119,
1542–1551.
13 Buts JP (1999) Bioactive factors in milk. Arch Pediatr 5,
298–306.
14 Kunz C, Rodriquez-Palmero M, Koletzko B & Jensen
R (1999) Nutritional and biochemical properties of
human milk: general aspects, proteins and carbohy-
drates. Clin Perinatol 26, 307–3033.
15 Groenink J, Walgreen-Weterings E, van’t Hof W, Veer-
man ECI & Amerongen AVN (1999) Cationic amphi-
pathic peptides, derived from bovine and human
lactoferrins, with antimicrobial activity against oral
pathogens. FEMS Microbiol Lett 179, 217–222.

R. V. Baudinette et al. Protection by eugenin of Macropus eugenii young
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 441
16 Wakabayashi H, Matsumoto H, Hashimoto K, Teragu-
chi S, Takase M & Hayasawa H (1999) Inhibition of
iron ⁄ ascorbate-induced lipid peroxidation by an N-ter-
minal peptide of bovine lactoferrin and its acylated
derivatives Biosci Biotechnol Biochem 63, 955–957.
17 Adamski FM & Demmer J (2000) Immunological pro-
tection of the vulnerable marsupial pouch young: two
periods of immune transfer during lactation in Tricho-
surus vulpecula (brushtail possum). Dev Comp Immunol
24, 491–502.
18 Taylor CL, Harrison GA, Watson CM & Deane EM
(2002) CDNA cloning of the polymeric immunoglobulin
receptor of the marsupial Macropus eugenii. Eur J
Immunogenetics 29, 87–93.
19 Nicholas KR, Messer M, Elliott C, Maher F & Shaw
DC (1987) A novel whey protein synthesised only in late
lactation by the mammary gland from the tammar
(Macropus eugenii). Biochem J 241, 899–904.
20 Collet C & Joseph R (1993) A novel member of the
lipocalin superfamily: tammar wallaby late lactation
protein. Biochem Biophys Acta 1167, 219–222.
21 Simpson KJ, Ranganathan S, Fisher JA, Janssens PA,
Shaw DC & Nicholas KR (2000) The gene for a novel
member of the whey acidic protein family encodes three
four-disulfide core domains and is asynchronously
expressed during lactation. J Biol Chem 275, 23074–
23081.
22 Oftedal OT (2002) The mammary gland and its origin

during synapsid evolution. J Mammary Gland Biol Neo-
plasia 7, 225–252.
23 Simpson KJ & Nicholas KR (2002) The comparative
biology of whey proteins. J Mammary Gland Biol Neo-
plasia 7, 313–326.
24 Goldman AS (2002) Evolution of the mammary gland
defense system and the ontology of the immune system.
J Mammary Gland Biol Neoplasia 7, 277–289.
25 Trott JF, Simpson KJ, Moyle RLC, Hearn CM, Shaw
G, Nicholas KR & Renfree MB (2003) Maternal regula-
tion of milk composition, milk production, and pouch
young development during lactation in the Tammar
wallaby. Biol Reprod 68, 929–936.
26 Hindes RD & Mizell M (1976) The origin of immuno-
globulins in oppossum ‘embryos’. Dev Biol 53, 49–61.
27 The Australian Museum Trust (1995) The Australian
Museum Complete Book of Australian Mammals. Reed
Books, Chatswood, NSW, Australia.
28 Hunkapiller MW, Hewick RM, Drewer WJ & Hood LE
(1983) High sensitivity sequencing with a gas-phase
sequencer. Methods Enzymol 91, 399–406.
29 Biemann K & Martin S (1987) Mass spectrometric
determination of the amino acid sequence of peptides
and proteins. Mass Spectrom Rev 6, 1–77.
30 Bowie JH, Brinkworth CS & Dua S (2002) Collision
induced fragmentations of (M-H)
–
parent anions of
peptides. An aid to structure determination and some
unusual anion chemistry. Mass Spectrom Rev 21, 87–

107.
31 Yagami T, Shiwa S, Futaki S & Kitagawa K (1993)
Evaluation of the final deprotection system for the
solid-state synthesis of Tyr (SO
3
H)-containing peptides
with 9-fluorenyl methoxycarbonyl (F-moc)-strategy and
its application to the synthesis of CCK8. Chem Pharm
Bull 41, 376–380.
32 Kitagawa K, Yagami T, Aida C, Fujiwara H, Futaki S,
Kogire M & Inoue K (1999) Desulfation vs. protection.
Direct solid-state synthesis of Tyr (SO
3
H)-containing
peptides using the S
N
1-type deprotection procedure. In
Peptide Science – Present and Future (Shimonixhi Y,
ed.), pp. 525–526. Kluwer Academic, Dordrecht, the
Netherlands.
33 Patel M & Spraggs CF (1992) Functional comparisons
of gastrin ⁄ cholecytokinin receptors in isolated prepara-
tions of gastric mucosa and ileum. Br J Pharmacol 106,
275–282.
34 Ahmed SA, Gogal RM Jr & Walsh JE (1994) A new
rapid and simple non-radioactive assay to monitor and
determine the proliferation of lymphocytes: an alterna-
tive to [
3
H]thymidine incorporation assay. J Immunol

Methods 170, 211–224.
35 Iwata N, Murayama T, Matsumori Y, Ito M, Nagata
A, Taniguchi T, Chikara K, Matsuo Y, Minowada J &
Matsui T (1996) Autocrine loop through cholecystoki-
nin-B ⁄ gastrin receptors involved in growth of human
leukemia cells. Blood 88 , 2683–2689.
36 Medina S, Rio MD, Cuadra BD, Guayerbas N &
Fuente MD (1999) Age related changes in the modula-
tory actrin of gastrin-releasing peptide, neuropeptide Y
and sulfated cholecystokinin octapeptide in the prolifera-
tion of murine lymphocytes. Neuropeptides 33, 173–179.
37 Dockray GJ (1976) Immunological evidence of cholecy-
stokinin-like peptides in brain. Nature 264, 568–570.
38 Matsumoto M, Park J, Sugano K & Yamada T (1987)
Biological activity of progastrin post-translational pro-
cessing intermediates. Am J Physiol 252, G315–G319.
39 Anastasi A, Erspamer V & Endean R (1968) Isolation
and amino acid sequence of caerulein, the active peptide
in the skin of Hyla caerulea. Arch Biochem Biophys 125,
57–68.
40 Erspamer V (1994) Bioactive secretions of the amphib-
ian integument. In Amphibian Biology (Heatwold H &
Barthalmus GT, eds), Vol. 1, pp. 214–231. Surrey
Beatty & Sons, Chipping Norton, NSW, Australia.
41 Wabnitz PA, Bowie JH & Tyler MJ (1999) Caerulein-
like peptides from the skin glands of the Australian Blue
Mountains Tree Frog Litoria citropa. Part 1. Sequence
determination using electrospray mass spectrometry.
Rapid Commun Mass Spectrom 13, 2498–2502.
42 Varga G, Balint A, Burghardt B & D’Amato M (2004)

Involvement of endhenous CCK and CCK
1
receptors in
colonic motor function. Br J Pharmacol 141, 1275–1284.
Protection by eugenin of Macropus eugenii young R. V. Baudinette et al.
442 FEBS Journal 272 (2005) 433–443 ª 2005 FEBS
43 Cuq P, Gross A, Terraza A, Fourmy D, Clerk P, Dor-
nand J & Magous R (1997) mRNAs encoding CCKB
but not CCKA receptors are expressed in human T lym-
phocytes and Jurkat lymphoblastoid cells. Life Sci 61,
543–555.
44 Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy
KB, Hamon M & Roques BJ (1999) Structure, distrubu-
tion and functions of cholecystokin receptors. Pharma-
col Rev 51, 745–781.
45 Pellegrini M & Mierke DF (1999) The complex of
CCK-8 and the N-terminus of CCKA receptor by
NMR spectroscopy. Biochemistry 38, 14775–14783.
46 Giragossian C & Mierke DF (2001) Intermolecular
interactions between CCK-8 and the third extracellular
loop of CCKA receptor. Biochemistry 40, 3804–3809.
47 Giragossian C & Mierke DF (2002) Intramolecular
interactions between CCK-8 and the third extracellular
loop of CCKB. Biochemistry 41, 4560–4566.
48 Dornand J, Roche S, Michel F, Bali JP, Cabane S,
Favero J & Magous R (1995) Gastrin CCK-B type
receptors on human T lymphoblastoid Jurkat cells. Am
J Physiol 268, G522–G529.
49 Alvery J, Stern E, Poticha S, Baunoch D & Adrian T
(1997) Cholecystokinin modulates mucosal immunoglo-

bulin A function. Surgery 122, 386–392.
50 Carrasco M, Hernanz A & De La Fuente M (1997)
Effect of cholecystokinin and gastrin on human
peripheral blood lymphocyte functions, implication
of cyclic AMP and interleukin 2. Regul Pept 70,
135–142.
51 Schnolzer M, Alewood PF, Jones A, Alewood D &
Kent SBH (1992) ‘In situ’ neutralisation protocols in
Boc-chemistry solid phase peptide synthesis: rapid, high
yield assembly of difficult sequences. Int J Pept Protein
Res 40, 180–193.
52 Alewood PF, Alewood D, Miranda L, Love S, Meuter-
mans WDF & Wilson D (1997) Rapid ‘in situ’ neutrali-
sation protocols for Boc and Fmoc solid-phase
chemistries. Methods Enzymol 289, 14–29.
53 Sarin VK, Kent SBH, Tam JP & Merrifield RB (1981)
Quantitative monitoring of solid-phase peptide synthesis
by the ninhydrin reaction. Anal Biochem 117, 147–157.
54 Kaiser E, Bossinger CD, Colescott RL & Olser DD
(1980) Color test for terminyl prolyl residues in the
solid-state synthesis of peptides. Anal Chem Acta 118,
149–151.
55 Pritchard CI & Auffret AD (1986) Quantitative analysis
in peptide synthesis: an improved method for proline
residues. Biochem Soc Trans 14, 1286–1287.
56 Jorgensen JH, Cleeland R, Craig WA, Doern G, Ferr-
aro MJ, Finegold SM, Hansen SL, Jenkins SG, Novick
WL, Pfaller MA, Preston DA, Reller LB & Swenson
JM (1993) Methods for antimicrobial tests for bacteria
that grow aerobically. In National Committee for Clini-

cal Laboratory Standards, Document M7-A3. Vol. 13,
Edn 3. p. 1. ISBN 1-56238-209-8, ISSN 0273-3099.
57 Hutchinson MR & Somogyi AA (2002) Diacetylmor-
phine degradation to 6-monoacetyl-morphine and mor-
phine in cell culture: implications for in vitro studies.
Eur J Pharmacol 453, 27–32.
58 Montecucchi PC, Falconieri Erspamer G & Visser J
(1977) Occurrence of Asn
2
, Leu
5
-caerulein in the skin of
the African frog Hylambates maculatus. Experientia 33,
1138–1139.
59 Anastasi A, Bertaccini G, Cei JM, DeCaro G, Erspamer
V & Impicciatore M (1969) Structure and pharmacolo-
gical actions of phyllocaerulein, a caerulein like nona-
peptide; its occurrence in extracts of the skin of
Phyllomedusa sauvagia and related Phyllomedusa species.
Br J Pharmacol 37, 198–206.
R. V. Baudinette et al. Protection by eugenin of Macropus eugenii young
FEBS Journal 272 (2005) 433–443 ª 2005 FEBS 443